A new shot is pushing thyroid patients' bulging eyes back where they belong

Thyroid eye disease can slowly push a person's eyes forward out of their sockets — along with double vision, staring looks, and sometimes permanent damage. A new Phase 3 trial in China tested an antibody injection, SYCUME (teprotumumab N01), on 116 people whose disease had gone quiet but left their eyes protruding — the form about two-thirds of patients live with. After 24 weeks, 60.4% of those who got the drug saw their eyes recede meaningfully, versus 23.5% on placebo, and the safety profile looked clean. The drug is already on China's national reimbursement list, so patients pay far less than the imported alternative. (This result comes from the drugmaker's own announcement, as is standard for topline trial data.)